New Threads Only:  Add to Google Reader or Homepage
New Threads & Replies:  Add to Google Reader or Homepage
Forums are for serious investors only. GuruFocus Forum Rules.

Forum List » Small Cap, Spin-Off, Risk Arbitrage
Share value ideas with market cap of a few billion or less. Spin-off, and risk arbitrage plays.
New Topic
Goto Thread: PreviousNext
Goto: Forum ListMessage ListNew TopicLog In
ReNeuron - undervalued Stem Cell company
Posted by: cf3 (IP Logged)
Date: October 1, 2012 04:27AM

Osiris MCap is $363,191,632 or £224,597,705
Osiris has cash/investments of $46,530,000 (£28,774,152) at 9 Aug 2012. It has a burn rate of $4,265,000 per quarter, so $17,060,000 (£10,549,904) a year. Therefore enough cash to last 2 year 9 months.

ReNeuron MCap is £27,860,000
ReNeuron had cash of about £10m in April and a burn rate of circa £5m a year. More importantly "we expect that our existing cash resources will be sufficient to support current operations until the end of the third quarter of 2013"

To reach the MCap of Qsiris, ReNeuron would be a 7-bagger, up 700% that is. Up from 3.2p to 25.6p per share.

ReNeuron were working on a JV deal with big pharma before the end of June. IMVHO it won't be much longer before they get that deal signed. My target for a deal, if I were on the BoD, would be by end of 2012.

From the 28 June 2012 RNS news announcement:
"We are also exploring the potential to reduce longer term funding requirements by the partnering of certain of our stem cell technologies and therapeutic programmes to commercial development partners in due course. Early discussions with interested parties have commenced in this regard."

My theory is that ReNeuron will get a JV deal with a big pharma soon, probably Merck because Merck Millipore are exclusive distributors of ReNeurons' stem cell test kits, a deal that will IMVHO bring in £20m+ of funding to take certain lines through to commercial sales.

With an extra £20m in cash to back it's lines to commercial sales you can compare ReNeuron directly to Osiris, as both will have about the same amount of cash, although ReNeuron will be burning it at half the rate that Osiris do, but are further ahead in their trials.

ii's already hold 447,318,687 shares, 57.73%. A JV deal with cash from Merck or similar would see that increase significantly as there would be very little chance of dilution, so the ii's could put the stock into 5 or 10 year funds and feel safe about it.
http://uk.reuters.com/business/quotes/financialHighlights?symbol=RQE.L

Comparing ReNeuron with Osiris I believe ReNeuron should already be 3x the MCap it is today. Up from 3.2p to 10p per share.

ReNeuron have not been accused of being misleading either.
http://www.forbes.com/sites/larryhusten/2012/07/05/stem-cell-therapy-company-hypes-preliminary-results/

ReNeuron RNS list
http://www.investegate.co.uk/Index.aspx?search&words=rene

Official Website
http://www.reneuron.com/

Broker target is 22p (587.5% above today's price!) which goes along with my MCap comparison to Osiris.
http://www.reneuron.com/latest-presentations


Rate this post:

Rating: 4.3/5 (4 votes)



Re: ReNeuron - undervalued Stem Cell company
Posted by: cf3 (IP Logged)
Date: October 1, 2012 04:31AM



Rate this post:

Rating: 4.6/5 (5 votes)



Re: ReNeuron - undervalued Stem Cell company
Posted by: cf3 (IP Logged)
Date: October 1, 2012 04:34AM

Some ReNeuron presentations.

http://www.gtcbio.com/preview/scsummit/slides/sinden_john.pdf

http://www.ucs.ac.uk/About/Events/Conferences/Regenerative-Medicine-summit/Trevor-Jones.pdf

This one is NOT available on the ReNeuron Website presentations page, so I doubt anyone here will have seen it yet. Spot the mentions of 'Multi-$billion market opportunity'.

Presentation to the EU Presidency High-Level Conference on “Healthy Ageing across the Lifecycle”, Cyprus, 5 September, 2012.

“Novel Stem Cell Therapies for the Diseases of Ageing - the Promise and the Challenges”

John Sinden - Chief Scientific Officer

http://www.cy2012.eu/index.php/fr/file/p7hY8H9WCWX2nxXo9+AUZw==

http://www.cy2012.eu/index.php/en/political-calendar/areas/employment-social-policy-health-consumer-affairs/healthy-ageing-across-the-lifecycle


Rate this post:

Rating: 4.8/5 (4 votes)



Re: ReNeuron - undervalued Stem Cell company
Posted by: cf3 (IP Logged)
Date: October 1, 2012 04:35AM

28 June 2012
"We are actively pursuing a range of future funding sources, including potentially non-dilutive sources such as grants.We are also exploring the potential to reduce longer term funding requirements by the partnering of certain of our stem cell technologies and therapeutic programmes to commercial development partners in due course. Early discussions with interested parties have commenced in this regard."

http://www.investegate.co.uk/Article.aspx?id=201206280700123340G

ReNeuron sell the stem cell products through Merck Millipore, a division of Merck Group. Merck would know all about ReNeuron technology and the several potential $bn markets for the products, so they are probably first in line for a JV deal. Such a deal would give the SP a huge boost and IMVHO it is not far away as ReNeuron have been working on this type of deal for a minimum of 3 months.

Merck Group:

"Merck is a global pharmaceutical, chemical and life science company with a history that began in 1668 and a future shaped by approximately 40,000 employees in 67 countries."
http://www.merckgroup.com/en/company/company.html

From the footer of news announcements:

"Merck is a global pharmaceutical and chemical company with total revenues of €10.3 billion in 2011, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries."

Merck Serono (ReNeuron products would fit into this division)
http://www.merckgroup.com/en/company/our_markets/about_merck_serono.html

A typical example of the kind of deal we could expect from Merck:

Merck Expands EGFR Targeted Portfolio by Acquiring Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 From Symphogen

Under the agreement, Merck will gain exclusive worldwide rights to develop and commercialize Sym004. In exchange, Symphogen will receive from Merck an upfront payment of €20 million as well as payments for clinical development, regulatory and sales performance milestones. Symphogen will also be eligible for potential royalties on net worldwide sales.

http://www.merckgroup.com/en/media/extNewsDetail.html?newsId=C324CD9323C1D43BC1257A700041E0F2&news

2012 financial report

http://www.merckgroup.com/en/investors/events_and_presentations/presentations_on_financial_results/business_result.html


Rate this post:

Rating: 4.2/5 (5 votes)





Sorry, only registered users may post in this forum.

Please Login if you have an account or Create a Free Account if you don't
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK